^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Peritoneal Cancer

1d
CATALYST: Choices About Genetic Testing And Learning Your Risk With Smart Technology (clinicaltrials.gov)
P=N/A, N=50, Completed, Rutgers, The State University of New Jersey | Active, not recruiting --> Completed
Trial completion
1d
KLK7 overexpression promotes an aggressive phenotype and facilitates peritoneal dissemination in colorectal cancer cells. (PubMed, FEBS Open Bio)
Additionally, KLK7 overexpression altered cell morphology, upregulated moesin (MSN) and integrin subunits, suggesting cytoskeletal remodeling and matrix interactions. Taken together, these findings suggest that KLK7 is a driver of CRC progression and could serve as a potential prognostic marker for aggressive forms of CRC.
Journal
|
KLK7 (Kallikrein Related Peptidase 7)
2d
Is There a Role of FAPI Pet in Renal and Bladder Cancer? (PubMed, Semin Nucl Med)
Early trials of FAPI-based radioligand therapies, including [¹⁷⁷Lu]FAPI-2286, show promising safety and preliminary efficacy. Based on the current premises, FAPI seems a promising agent for genitourinary oncology, requiring further assessment through prospective studies.
Review • Journal
|
FAP (Fibroblast activation protein, alpha)
6d
Pathological complete response to pembrolizumab in recurrent retroperitoneal dedifferentiated liposarcoma with high tumor mutational burden: a case report. (PubMed, World J Surg Oncol)
This is the first reported case of recurrent retroperitoneal DDLPS with high TMB achieving pCR to pembrolizumab. High TMB and high TAM density in the tumor microenvironment may be predictive biomarkers for the response to ICIs in DDLPS.
Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
PD-L1 expression • TMB-H • PD-L1 negative
|
Keytruda (pembrolizumab) • doxorubicin hydrochloride • pazopanib • Halaven (eribulin mesylate)
8d
Preoperative tumor marker elevations in lymph node positive appendiceal mucinous neoplasms with peritoneal metastases. (PubMed, Eur J Surg Oncol)
Preoperative CEA elevation >5 in 13 patients showed a median survival of 3 years as compared to 15 patients (53.6 %) with non-elevated CEA with a median survival of 16 years. Preoperative CEA measurement may signal an aberrant tumor biology that indicates patients at high risk of treatment failure for CRS and HIPEC.
Review • Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
8d
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT (clinicaltrials.gov)
P1/2, N=22, Recruiting, Case Comprehensive Cancer Center | Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Mar 2026
Trial completion date • Trial primary completion date
11d
Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer. (PubMed, JCO Oncol Pract)
In two data sets, the tumor chemosensitivity assessed by the KELIM (online calculator)29 was a consistent significant predictor of three critical outcomes associated with successful ICS after NACT. The radiologic response was inconsistently associated with lower disease bulk. The BRCA/HRD status was not predictive of NACT efficacy. These outcomes may inform decisions and future chemosensitizing innovative strategies.
Journal
|
HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
|
HRD
11d
Severe, refractory paraneoplastic aplastic anemia secondary to primary peritoneal carcinoma: a case report. (PubMed, Gynecol Oncol Rep)
She received granulocyte colony-stimulating factor (GCSF), thrombopoietin (TPO) mimetic, and immunosuppressive therapy with prednisone prior to primary cytoreductive surgery to no apparent gross residual disease...She was treated with anti-thymocyte globulin (ATG) and cyclosporine and subsequently received adjuvant chemotherapy with weekly cisplatin and subsequent addition of weekly paclitaxel, resulting in reduction in her serum Cancer Antigen-125 (CA-125) and no radiographic evidence of disease. Despite initial response, her clinical deterioration and her decision to forego further cancer- or aplastic anemia-directed therapy resulted in transition to home hospice care, and she was discharged 119 days after admission. This case report highlights the importance of multi-disciplinary collaboration to manage the medical complexities of paraneoplastic aplastic anemia secondary to a gynecologic malignancy.
Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • MUC16 (Mucin 16, Cell Surface Associated)
|
cisplatin • paclitaxel • prednisone
11d
Adipocytes are dispensable in shaping the ovarian cancer tumor microenvironment in the omentum. (PubMed, bioRxiv)
Indeed, endothelial cell-selective deficiency of FABP4 reduced OC growth in the peritoneum. These findings prompt a reevaluation of adipocyte contributions to OC progression and suggest a key role of the omental vasculature in supporting OC metabolic growth.
Journal
|
BRCA2 (Breast cancer 2, early onset) • FABP4 (Fatty Acid Binding Protein 4)
14d
Patterns of progressive disease in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer treated with immune checkpoint inhibitor(s): Different entities requiring tailored management. (PubMed, Eur J Cancer)
PD under ICI(s) in dMMR/MSI-H mCRC follows distinct patterns, with overall survival < 1 year in case of early-PD. Oligo-PD accounts for half of secondary resistance and is associated with favorable survival, offering an opportunity for focal ablative therapies, and highlighting the need for personalized post-progression management.
Journal • Checkpoint inhibition • Microsatellite instability • MSI-H
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
15d
Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer (clinicaltrials.gov)
P=N/A, N=94, Recruiting, Shanghai Gynecologic Oncology Group | Not yet recruiting --> Recruiting | Phase classification: P2 --> PN/A | N=69 --> 94
Enrollment open • Phase classification • Enrollment change
15d
Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions (clinicaltrials.gov)
P2, N=106, Recruiting, Nizhny Novgorod Regional Clinical Oncology Center | Trial completion date: Jan 2026 --> Sep 2027 | Trial primary completion date: Jan 2026 --> Jul 2026
Trial completion date • Trial primary completion date
|
docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium